Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $23.
October 25, 2024 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Inozyme Pharma and maintained a price target of $23, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst suggests a positive outlook for Inozyme Pharma. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100